MARKET

HROW

HROW

Harrow Health Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.95
+0.39
+5.16%
After Hours: 7.80 -0.15 -1.89% 16:24 03/05 EST
OPEN
7.48
PREV CLOSE
7.56
HIGH
7.98
LOW
7.01
VOLUME
273.28K
TURNOVER
--
52 WEEK HIGH
11.10
52 WEEK LOW
3.330
MARKET CAP
204.68M
P/E (TTM)
-78.4024
1D
5D
1M
3M
1Y
5Y
Harrow Health to Participate in H.C. Wainwright Global Life Sciences Conference
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the H.C. Wainwright Global Life Sciences Conference to be h...
GlobeNewswire · 5d ago
Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for
Zacks.com · 03/01 06:03
Harrow Health to Announce Fourth Quarter and Year-End 2020 Financial Results on March 8, 2021
NASHVILLE, Tenn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2020, on Monday,...
GlobeNewswire · 02/25 14:00
Harrow Health Subsidiary Melt Pharmaceuticals Says Completes Phase 1 Study For Sublingual, Non-Opioid Pain And Sedation Drug Candidate; Melt CEO Says 'The data established relative bioavailability and important pharmacokinetic parameters'
"We are pleased with the results of our Phase 1 MELT study, which marks another important milestone for the Company," said Greg Madison, CEO of Melt Pharmaceuticals. "The data established relative
Benzinga · 02/09 12:16
The Harrow Health (NASDAQ:HROW) Share Price Is Up 456% And Shareholders Are Delighted
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Mistakes are...
Simply Wall St. · 02/04 07:25
The Harrow Health (NASDAQ:HROW) Share Price Is Up 456% And Shareholders Are Delighted
Simply Wall St. · 02/04 07:25
CLSK, ISR, SYN and BBI among midday movers
Gainers: Isoray (ISR) +187%.The9 (NCTY) +48%.9 Meters Biopharma (NMTR) +40%.AIkido Pharma (AIKI) +40%.Guardion Health Sciences (GHSI) +38%.TAT Technologies (TATT) +35%.Orchard Therapeutics (ORTX) +35%.Change Healthcare (CHNG) +31%.CleanSpark (CLSK) +30%.CBAK Energy Technology (CBAT) +28%.Losers: IMARA (IMRA) -35%.Second Sight Medical Products (EYES) -23%.Mexco
Seekingalpha · 01/06 17:47
Zacks Industry Outlook Highlights: Apollo Medical, bioMerieux, CareDx and Harrow Health
Zacks Industry Outlook Highlights: Apollo Medical, bioMerieux, CareDx and Harrow Health
Zacks · 12/18/2020 16:22
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HROW. Analyze the recent business situations of Harrow Health Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HROW stock price target is 13.50 with a high estimate of 14.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 113
Institutional Holdings: 13.89M
% Owned: 53.94%
Shares Outstanding: 25.75M
TypeInstitutionsShares
Increased
37
1.14M
New
18
102.07K
Decreased
11
320.36K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
Robert Kammer
Chief Executive Officer/Director
Mark Baum
Chief Financial Officer/Secretary
Andrew Boll
Corporate Executive
John Saharek
Other
Larry Dillaha
Director
Richard Lindstrom
Other
Dennis Saadeh
Independent Director
Teresa Sparks
Independent Director
R. Lawrence Van Horn
No Data
About HROW
Harrow Health, Inc owns a portfolio of healthcare and ophthalmology pharmaceutical business, including ImprimisRx, an ophthalmology outsourcing facility and pharmaceutical compounding business. The Company holds interest in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals. The Company also owns royalty rights in four clinical stage drug candidates, which is being developed by Surface Ophthalmics and Melt Pharmaceuticals.

Webull offers kinds of Harrow Health Inc stock information, including NASDAQ:HROW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HROW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HROW stock methods without spending real money on the virtual paper trading platform.